Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer
Clinical Immunology · 2026-06 · 285 · 110697
DOI: 10.1016/j.clim.2026.110697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2026-06. Verfasst von Fangfang Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Education, Puyang Medical College, 457000 Puyang, China; Henan Institute of Medical and Pharmaceutical Sciences, Zhengzho…. Hauptthemen laut MEDLINE: Autoantibodies, Breast Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Hainan Association for Science and Technology.
Abstract (Originalsprache)
Autoantibodies have emerged as highly valuable biomarkers for cancer detection. Ferredoxin 1 (FDX1), a key cuproptosis regulator, significantly influences breast cancer prognosis. This study aimed to investigate whether the anti-FDX1 autoantibody can serve as a novel biomarker for breast cancer detection and diagnosis. Anti-FDX1 levels were detected in plasma from 336 breast cancer patients (BC), 220 patients with benign breast nodule (BBN), and 236 normal controls (NC) using ELISA assay. Anti-FDX1 levels in BC were lower than that in NC and BBN. Subgroup analysis revealed enhanced diagnostic efficacy in Luminal A patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Education, Puyang Medical College, 457000 Puyang, China; Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, 450052 Zhengzhou, China.
- Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, China.
- Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, 450052 Zhengzhou, China.
- Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, 450052 Zhengzhou, China. Electronic address: ljj903@hotmail.com.
Förderung
- Hainan Association for Science and Technology
Zitieren
APA
Liu, F., Qu, Y., Yu, P., & Liu, J. (2026). Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer. Clinical Immunology, 285, 110697. https://doi.org/10.1016/j.clim.2026.110697
Vancouver
Liu F, Qu Y, Yu P, Liu J. Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer. Clinical Immunology. 2026;285:110697. doi:10.1016/j.clim.2026.110697
BibTeX
@article{Liu2026,
author = {Liu, Fangfang and Qu, Yunhui and Yu, Peiqi and Liu, Jingjing},
title = {Plasma anti-FDX1 autoantibody as a potential biomarker for detection and diagnosis of breast cancer},
journal = {Clinical Immunology},
year = {2026},
volume = {285},
pages = {110697},
doi = {10.1016/j.clim.2026.110697}
}
EUVIMED